RALBP1

ralA binding protein 1

Basic information

Region (hg38): 18:9475009-9538114

Links

ENSG00000017797 ∙ NCBI:10928 ∙ OMIM:605801 ∙ HGNC:9841 ∙ Uniprot:Q15311 ∙ AlphaFold ∙ GenCC ∙ jax ∙ Sfari ∙ GnomAD ∙ Pubmed ∙ ClinVar

Transcripts

Transcript IDs starting with ENST are treated as Ensembl, all others as RefSeq. Showing 4 of 34.

Transcript ID	Protein ID	Coding exons	MANE Select	MANE Plus Clinical
ENST00000019317.8	ENSP00000019317.4	9	-	-
ENST00000383432.8	ENSP00000372924.3	9	yes	-
ENST00000458039.3	ENSP00000411556.3	2	-	-
ENST00000577221.1	ENSP00000462549.1	1	-	-

Phenotypes

GenCC

Source: genCC

No genCC data.

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the RALBP1 gene.

• not_specified (76 variants)
• not_provided (7 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the RALBP1 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000006788.4. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Effect	Pathogenic	Likely pathogenic	VUS	Likely benign	Benign	Sum
synonymous				4		4
missense			78	3	2	83
nonsense						0
start loss						0
frameshift						0
splice donor/acceptor (+/-2bp)			1			1
Total	0	0	79	7	2

GnomAD

Source: gnomAD

Gene	Type	Bio Type	Transcript	Coding Exons	Length
RALBP1	protein_coding	protein_coding	ENST00000019317	9	63108

pLI Probability LOF Intolerant	pRec Probability LOF Recessive	Individuals with no LOFs	Individuals with Homozygous LOFs	Individuals with Heterozygous LOFs	Defined	p
		125719	0	29	125748	0.000115

	Z-Score	Observed	Expected	Observed/Expected	Mutation Rate	Total Possible in Transcript
Missense	2.01	254	361	0.703	0.0000204	4341
Missense in Polyphen		42	83.523	0.50285		1220
Synonymous	0.485	129	136	0.947	0.00000815	1180
Loss of Function	3.94	8	32.1	0.249	0.00000182	393

LoF frequencies by population

Ethnicity	Sum of pLOFs	p
African & African-American	0.000138	0.000123
Ashkenazi Jewish	0.0000996	0.0000992
East Asian	0.00	0.00
Finnish	0.000487	0.000462
European (Non-Finnish)	0.000140	0.000132
Middle Eastern	0.00	0.00
South Asian	0.00	0.00
Other	0.000163	0.000163

dbNSFP

Source: dbNSFP

• Function: FUNCTION: Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the multidrug resistance phenomenon. Serves as a scaffold protein that brings together proteins forming an endocytotic complex during interphase and also with CDK1 to switch off endocytosis, One of its substrates would be EPN1/Epsin. {ECO:0000269|PubMed:11437348, ECO:0000269|PubMed:12775724, ECO:0000269|PubMed:7673236}.
• Pathway: Doxorubicin Pathway (Cancer Cell), Pharmacodynamics;Ras signaling pathway - Homo sapiens (human);Doxorubicin Pathway, Pharmacokinetics;Pathways in cancer - Homo sapiens (human);Carbamazepine Pathway, Pharmacokinetics;Pancreatic cancer - Homo sapiens (human);Vinka Alkaloid Pathway, Pharmacokinetics;Doxorubicin Metabolism Pathway;Vincristine Action Pathway;Vinblastine Action Pathway;Vinorelbine Action Pathway;Vindesine Action Pathway;RalA downstream regulated genes;Ras Signaling;EGF-EGFR Signaling Pathway;Signal Transduction;ras signaling pathway;rho cell motility signaling pathway;t cell receptor signaling pathway;rac1 cell motility signaling pathway;Rho GTPase cycle;adp-ribosylation factor;Signaling by Rho GTPases;EGFR1;Regulation of RAC1 activity;Regulation of CDC42 activity (Consensus)

Recessive Scores

• pRec: 0.171

Intolerance Scores

• loftool: 0.390
• rvis_EVS: -0.38
• rvis_percentile_EVS: 27.88

Essentials

• essential_gene_CRISPR: N
• essential_gene_CRISPR2: N
• essential_gene_gene_trap: N
• gene_indispensability_pred: E
• gene_indispensability_score: 0.935

Gene Damage Prediction

	All	Recessive	Dominant
Mendelian	Medium	Medium	Medium
Primary Immunodeficiency	Medium	Medium	Medium
Cancer	Medium	Medium	Medium

Gene ontology

• Biological process: drug transmembrane transport;endocytosis;chemotaxis;signal transduction;small GTPase mediated signal transduction;regulation of GTPase activity;positive regulation of GTPase activity;regulation of small GTPase mediated signal transduction;transmembrane transport;doxorubicin transport
• Cellular component: cytosol;membrane
• Molecular function: GTPase activator activity;protein binding;drug transmembrane transporter activity;Ral GTPase binding;transmembrane transporter activity;ATPase activity, coupled to transmembrane movement of substances;Rac GTPase binding